The combination of cyclosporine 0.05% 0.1%-loteprednol 0.2% provided significant improvement in corneal higher-order aberrationswhen compared with cyclosporine 0.05% Clinical Ophthalmology.
A study was done to examine the efficacy and tolerability of a combination of cyclosporine 0.1% and loteprednol 0.2% (CsA–LE; Klarity CL) in comparison to commercially available cyclosporine 0.05% (CsA; Restasis) in improving signs and symptoms of dry eye.
This multicenter, prospective, randomized, controlled, open-label study evaluated 60 patients randomized to a single treatment for 4 weeks and evaluated at day 0, day 14, and day 28. The comparison was made of corneal higher-order aberrations (HOAs), dry-eye symptoms (SPEED score), tear-breakup time (TBUT), corneal staining, and ocular hyperemia, as well as tolerability of each medication with the validated COMTOL instrument.
Results
A total of 56 patients completed enrollment. Corneal HOAs improved significantly with cyclosporine 0.05% –loteprednol, but not cyclosporine 0.05% alone. Both groups showed significant improvement (with no significant differences between groups) in SPEED scores, corneal staining, TBUT, and conjunctival hyperemia. Tolerability was similar between the drugs, and no significant safety issues were identified.
The combination of cyclosporine 0.05% 0.1%–loteprednol 0.2% provided significant improvement in corneal higher-order aberrations, while v0.05% did not. For all other measures of ocular surface improvement, both medications showed similar benefits. Tolerability was comparable between the formulations. When rapid rehabilitation of the ocular surface is needed to reduce aberrations, cyclosporine 0.05% –loteprednol is an appropriate choice.
Reference:
John Hovanesian, Thomas Chester & Robert C Sorenson (2023) A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye, Clinical Ophthalmology, 17:, 2181-2191, DOI: 10.2147/OPTH.S419600
Keywords;
John Hovanesian, Thomas Chester & Robert C Sorenson, Prospective, Study, Cyclosporine, 0.1% Combined, Loteprednol, 0.2% Cyclosporine, 0.05, Alone, Treatment of Dry Eye, Clinical Ophthalmology, higher-order aberrations